Scientists hunt for clues to stop Trial-and-Error in kidney treatment
NCT ID NCT07416942
Summary
This study aims to help doctors predict which patients with a kidney disease called membranous nephropathy will respond well to a common treatment called rituximab. Researchers will analyze stored blood and tissue samples from 120 patients to look for genetic and molecular markers linked to treatment success or failure. The goal is to move from a 'trial-and-error' approach to personalized medicine, ensuring patients get the most effective therapy sooner.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Research Centre for Rare Diseases Aldo e Cele Daccò
Ranica, BG, 24020, Italy
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.